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Too often, negative
trials are viewed as
failures.
I reminded him
that disproving a
hypothesis is per-
haps the greatest
contribution of the
scientific method
and should not be
viewed as failure.
As we move further
into the era of cost
containment in
medical investiga-
tion and rely more
on observational
studies of popula-
tions, we must not
forget the value of
randomized con-
trolled trials that
point out the holes
in our “conven-
tional wisdom.”DITOR’S PAGE
on’t Be Negative on Negative Trials
oo often, negative trials are viewed as failures. Great effort is put into designing and execut-
ng a trial with an end point, which if reached, may prove the value of the therapy. If the end
oint is not reached, the value of the therapy is not proved. This does not mean that the ther-
py is proved to be of no value.
Recently, I tried to explain the value of some negative trials to a friend who knows a lot
bout winning and losing, as in, “Did your team win the Super Bowl or lose the Super Bowl?”
e is a very positive guy, is a huge sports fan, and abhors a tie. My explanation to him about
he value of trials that were not positive left him somewhat baffled. This conversation came
fter the first couple of days of the American Heart Association (AHA) meeting in Chicago.
e asked me, “What is happening at the American Heart Association meeting?” I told him
hat most of the trials that were being reported were negative and he said, “That’s too bad.”
ut, was it?
Negative trials far outweighed positive trials in the late-breaking trial category reported at
he AHA. Among the trials being reported were the CLOSURE I (Safety and Efficacy of the
TARFlex Septal Closure System vs. Best Medical Therapy in Patients with a Stroke or TIA
ue to Presumed Paradoxical Embolism Through a PFO) (1) trial, which failed to show that
outine percutaneous closure device placement for patent foramen ovale (PFO) reduced the
hance of subsequent stroke; the SMART AV (SmartDelay Determined AV Optimization: A
omparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy) (2)
rial, which failed to show that routine echocardiography following resynchronization therapy
or congestive heart failure improved outcomes; the GRAVITAS (Gauging Responsiveness
ith A VerifyNow Assay–Impact on Thrombosis and Safety) (3) trial, which failed to show a
ignificant reduction in events with doubling of the clopidogrel dose after stent placement; and
everal more. My friend interpreted this news as a failure to get value for the significant
xpenditures involved in performing these trials. I reminded him that disproving a hypothesis
s perhaps the greatest contribution of the scientific method and should not be viewed as
ailure.
He said, “I understand. The trials you listed were really not negative but positive in proving
hat no PFOs should be closed, no one should have an increased dose of clopidogrel, and
chocardiography should never be done on patients who had recent resynchronization therapy.”
e went on, “This is really very positive news because it shows we can save a great deal of
oney by eliminating PFO closures, increased clopidogrel dosing, and echocardiography for
hose patients.” This is unfortunately the “black and white,” “either/or” thinking that is
eflected by sound bites and headlines. More importantly, it is often the only thing that
atients and payers hear. The nuisances of negative trials, including the very important
uestions of who are the subjects, what is the design, was the result consistent across
ubgroups, and many others, are not asked often enough. Evidence generated from medical
esearch is seldom absolute, but it is an evolution that moves us closer to the truth.
My friend said, “So these trials will not change anything?” Of course they will. Routine
ractice will not be to close all PFOs, to double the dose of clopidogrel, or to do
chocardiograms. To the degree that these practices were routine there will be changes in
ractice. Just as the much-discussed COURAGE trial failed to show improved survival by
outine stenting for stable ischemic heart disease, it did not prove that stenting should not be
one in selected patients with stable ischemic heart disease. Perhaps the greatest value will be
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135o help design the next trial to work toward the goal of
dentifying which patients should have the therapy.
As we move further into the era of cost containment in
edical investigation and rely more on observational
tudies of populations, we must not forget the value of
andomized controlled trials that point out the holes in
ur “conventional wisdom.” At the same time, it is
mportant to take into account the findings of negative
rials in formulating the next question to be asked.
erhaps some of those questions should be: Are there
FOs that should be closed and how can these be
dentified? Are there patients who require more
ntiplatelet therapy, and what role can doubling the
lopidogrel dose play when generic formulations are
vailable? And, which patients who haven’t shown
mprovement from resynchronization therapy should have
chocardiographic guidance of different pacing modalities?
r, in the post-COURAGE world, which patients withocumented ischemia will benefit from revascularization?
3one of these questions were answered by the negative
rials reported, but the questions could not have been
ntelligently asked without the findings of the negative
rials. Are these trials failures? Far from it. They are of
reat value, as I told my friend.
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